TheEdgeResearch
Home / Stocks / APUS

Apimeds Pharmaceuticals US, Inc (APUS)

AMEX Healthcare Biotechnology
$7.25 ▲ +47.36%
Market Cap
$10.9M
Sector
Healthcare
Industry
Biotechnology
Beta
0.15
52-Wk Range
1.51-59.7
CEO
Vinod Menon
Country
US
Currency
USD

Apimeds Pharmaceuticals US, Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Matawan, NJ, US. The stock last traded at $7.25, up 47.36% on the session, giving a market capitalisation of $10.9M. On trailing twelve-month figures it carries a trailing P/E of -0.15, a net margin of 0.0%. Its beta of 0.15 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.15
Price / Sales
0.00
Price / Book
0.11
EV / EBITDA
-0.47
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.14
Current ratio
0.51
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange Arca
Employees
7
IPO date
2025-05-09
Headquarters
Matawan, NJ, US
About Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Comparable companies

Apimeds Pharmaceuticals US, Inc is most often compared with the following Healthcare names:

ANTXIGCMIRAMLSSMYONXTCPOCIQTTBSCYXTLPH
More research on APUS
APUS technical analysis APUS TheEdge Score Compare against peers
Open full interactive analysis & DCF →